Australia Federal Court Dismisses Cancer Patients' Challenge to Myriad's Gene Patent | GenomeWeb

NEW YORK (GenomeWeb News) – The Federal Court of Australia has dismissed a case in which a group of cancer patients were challenging the viability of a patent held by Myriad Genetics covering mutations in the BRCA1 gene linked to increased risk of hereditary breast and ovarian cancer.

Under Australian patent law, human beings and the biological processes involved in the creation of human beings are not patentable, but any "manner of manufacture," claims that are novel, inventive and useful, are patentable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.